Neutralizing Monoclonal Antibodies to Botulinum Neurotoxin Type A


Two chimpanzee mAbs specifically reacted with light chain of the botulinum neurotoxin A and neutralize the toxin in the mouse model. They can be used for emergency prophylaxis and treatment of either naturally acquired or terrorist associated botulism. Since the sequence of chimpanzee immune globulin is virtually identical to that of humans, the MAbs are not expected to have problems in repeated administration as equine antibodies. They can also be used for rapid diagnosis of botulinum neurotoxin A.

Potential Commercial Applications: Competitive Advantages:
  • A research material that can be used in the development of assays, validation of products or in quality control.
 
  • Speed up product development with NIH developed material that has already been tested and validated.


Inventors:

Robert Purcell (NIAID)  ➽ more inventions...

Zhaochun Chen (NIAID)  ➽ more inventions...

Suzanne Emerson (NIAID)  ➽ more inventions...


Intellectual Property:
Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2006-059)

Licensing Contact:
Jenish Patel, Ph.D.
Email: jenish.patel@nih.gov
Phone: 240-669-2894

OTT Reference No: E-180-2006/0
Updated: Nov 6, 2017